金吾财讯 | 礼来(LLY)公布实验性减肥药临床试验结果。公司测试奥格利普龙（Orforglipron）的药物在糖尿病、肥胖症以及睡眠呼吸暂停等相关疾病中的作用，实验性药物Orforglipron在后期试验中，最高剂量下可使 2 型糖尿病患者体重减轻16.0 磅（7.9%），并降低血糖。礼来公司表示，研究结束时患者尚未达到体重平台期，这表明患者减重幅度可能更大。
投资者和分析师此前预计，该药物的疗效至少会与诺和诺德公司（Novo Nordisk）旗下的重磅糖尿病药物奥泽匹克（Ozempic）一样好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.